130 related articles for article (PubMed ID: 37702430)
21. Targeted therapy with anlotinib for a H3K27M mutation diffuse midline glioma patient with PDGFR-α mutation: a case report.
Wang Q; Niu W; Pan H
Acta Neurochir (Wien); 2022 Aug; 164(8):2063-2066. PubMed ID: 34812950
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic avenues for targeting treatment challenges of diffuse midline gliomas.
Noon A; Galban S
Neoplasia; 2023 Jun; 40():100899. PubMed ID: 37030112
[TBL] [Abstract][Full Text] [Related]
23. Clinically Relevant and Minimally Invasive Tumor Surveillance of Pediatric Diffuse Midline Gliomas Using Patient-Derived Liquid Biopsy.
Panditharatna E; Kilburn LB; Aboian MS; Kambhampati M; Gordish-Dressman H; Magge SN; Gupta N; Myseros JS; Hwang EI; Kline C; Crawford JR; Warren KE; Cha S; Liang WS; Berens ME; Packer RJ; Resnick AC; Prados M; Mueller S; Nazarian J
Clin Cancer Res; 2018 Dec; 24(23):5850-5859. PubMed ID: 30322880
[TBL] [Abstract][Full Text] [Related]
24. An EZH2 blocker sensitizes histone mutated diffuse midline glioma to cholesterol metabolism inhibitors through an off-target effect.
Rahal F; Capdevielle C; Rousseau B; Izotte J; Dupuy JW; Cappellen D; Chotard G; Ménard M; Charpentier J; Jecko V; Caumont C; Gimbert E; Grosset CF; Hagedorn M
Neurooncol Adv; 2022; 4(1):vdac018. PubMed ID: 35300150
[TBL] [Abstract][Full Text] [Related]
25. A three-dimensional (3D) organotypic microfluidic model for glioma stem cells - Vascular interactions.
Truong D; Fiorelli R; Barrientos ES; Melendez EL; Sanai N; Mehta S; Nikkhah M
Biomaterials; 2019 Apr; 198():63-77. PubMed ID: 30098794
[TBL] [Abstract][Full Text] [Related]
26. Epigenome Programming by H3.3K27M Mutation Creates a Dependence of Pediatric Glioma on SMARCA4.
Mo Y; Duan S; Zhang X; Hua X; Zhou H; Wei HJ; Watanabe J; McQuillan N; Su Z; Gu W; Wu CC; Vakoc CR; Hashizume R; Chang K; Zhang Z
Cancer Discov; 2022 Dec; 12(12):2906-2929. PubMed ID: 36305747
[TBL] [Abstract][Full Text] [Related]
27. Differences in survival prognosticators between children and adults with H3K27M-mutant diffuse midline glioma.
Gong X; Kuang S; Deng D; Wu J; Zhang L; Liu C
CNS Neurosci Ther; 2023 Dec; 29(12):3863-3875. PubMed ID: 37311690
[TBL] [Abstract][Full Text] [Related]
28. Glioma stem cells are more aggressive in recurrent tumors with malignant progression than in the primary tumor, and both can be maintained long-term in vitro.
Huang Q; Zhang QB; Dong J; Wu YY; Shen YT; Zhao YD; Zhu YD; Diao Y; Wang AD; Lan Q
BMC Cancer; 2008 Oct; 8():304. PubMed ID: 18940013
[TBL] [Abstract][Full Text] [Related]
29. Case Report: Five Adult Cases of H3K27-Altered Diffuse Midline Glioma in the Spinal Cord.
Gu Q; Huang Y; Zhang H; Jiang B
Front Oncol; 2021; 11():701113. PubMed ID: 34956856
[TBL] [Abstract][Full Text] [Related]
30. SHP-2-upregulated ZEB1 is important for PDGFRα-driven glioma epithelial-mesenchymal transition and invasion in mice and humans.
Zhang L; Zhang W; Li Y; Alvarez A; Li Z; Wang Y; Song L; Lv D; Nakano I; Hu B; Cheng SY; Feng H
Oncogene; 2016 Oct; 35(43):5641-5652. PubMed ID: 27041571
[TBL] [Abstract][Full Text] [Related]
31. Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategies.
Findlay IJ; De Iuliis GN; Duchatel RJ; Jackson ER; Vitanza NA; Cain JE; Waszak SM; Dun MD
Oncogene; 2022 Jan; 41(4):461-475. PubMed ID: 34759345
[TBL] [Abstract][Full Text] [Related]
32. A novel CDK4/6 inhibitor combined with irradiation demonstrates potent anti-tumor efficacy in diffuse midline glioma.
Zuo P; Li Y; Wang T; Lin X; Wu Z; Zhang J; Liao X; Zhang L
J Neurooncol; 2023 May; 163(1):159-171. PubMed ID: 37133743
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Indicators for H3K27M-Mutant Diffuse Midline Glioma: A Population-Based Retrospective Surveillance, Epidemiology, and End Results Database Analysis.
Adhikari S; Bhutada AS; Ladner L; Cuoco JA; Entwistle JJ; Marvin EA; Rogers CM
World Neurosurg; 2023 Oct; 178():e113-e121. PubMed ID: 37423332
[TBL] [Abstract][Full Text] [Related]
34. A homogeneous treatment for non-DIPG diffuse midline glioma.
Schiavello E; Biassoni V; Gattuso G; Podda M; Chiaravalli S; Barretta F; Antonelli M; De Cecco L; Pecori E; Gandola L; Massimino M
Tumori; 2023 Jun; 109(3):269-275. PubMed ID: 35708347
[TBL] [Abstract][Full Text] [Related]
35. [Clinicopathological characteristics and prognosis of diffuse midline gliomas with histone H3K27M mutation: an analysis of 30 cases].
Li HN; Shan CG; Fan CZ; Cheng LN; Wu SG; Liu MT; Jiang GY; Li Z
Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):192-198. PubMed ID: 30831644
[No Abstract] [Full Text] [Related]
36. Extra-neural metastases in pediatric diffuse midline gliomas, H3 K27-altered: presentation of two cases and literature review.
De Martino L; Picariello S; Russo C; Errico ME; Spennato P; Papa MR; Normanno N; Scimone G; Colafati GS; Cacchione A; Mastronuzzi A; Massimino M; Cinalli G; Quaglietta L
Front Mol Neurosci; 2023; 16():1152430. PubMed ID: 37547920
[TBL] [Abstract][Full Text] [Related]
37. INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas.
Grassl N; Sahm K; Süße H; Poschke I; Bunse L; Bunse T; Boschert T; Mildenberger I; Rupp AK; Ewinger MP; Lanz LM; Denk M; Tabatabai G; Ronellenfitsch MW; Herrlinger U; Glas M; Krex D; Vajkoczy P; Wick A; Harting I; Sahm F; von Deimling A; Bendszus M; Wick W; Platten M
Neurol Res Pract; 2023 Oct; 5(1):55. PubMed ID: 37853454
[TBL] [Abstract][Full Text] [Related]
38. Venetoclax Cooperates with Ionizing Radiation to Attenuate Diffuse Midline Glioma Tumor Growth.
Madhavan K; Balakrishnan I; Lakshmanachetty S; Pierce A; Sanford B; Fosmire S; Elajaili HB; Walker F; Wang D; Nozik ES; Mitra SS; Dahl NA; Vibhakar R; Venkataraman S
Clin Cancer Res; 2022 Jun; 28(11):2409-2424. PubMed ID: 35344040
[TBL] [Abstract][Full Text] [Related]
39. AURKA and PLK1 inhibition selectively and synergistically block cell cycle progression in diffuse midline glioma.
Metselaar DS; du Chatinier A; Meel MH; Ter Huizen G; Waranecki P; Goulding JR; Bugiani M; Koster J; Kaspers GJL; Hulleman E
iScience; 2022 Jun; 25(6):104398. PubMed ID: 35637734
[TBL] [Abstract][Full Text] [Related]
40. Adult diffuse midline gliomas H3 K27-altered: review of a redefined entity.
López-Pérez CA; Franco-Mojica X; Villanueva-Gaona R; Díaz-Alba A; Rodríguez-Florido MA; Navarro VG
J Neurooncol; 2022 Jul; 158(3):369-378. PubMed ID: 35567713
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
